Physicians have spent years working to improve the care for women in menopause and perimenopause − from training providers to setting standards for hormone replacement therapy.
Now they fear a lack of access to the most common medication prescribed for menopause could undo this work. And they are asking the Food and Drug Administration to do more.
A group of women, led by the founders of Midi Health, the largest provider of menopause care in the United States, is meeting with FDA officials on Wednesday, May 6, to talk about solutions for the estrogen patch shortage.
Estrogen patches have been in short supply since the start of the year.
The FDA told USA TODAY in April that the organization was talking with the five biggest patch manufacturers, ensuring all companies are running at capacity. Officials said they weren’t yet categorizing the difficulty in finding the patch as a shortage, but some providers and patients disagree.
